Maja Bujas‐Bobanovic

993 total citations
29 papers, 731 citations indexed

About

Maja Bujas‐Bobanovic is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Maja Bujas‐Bobanovic has authored 29 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Surgery, 11 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Economics and Econometrics. Recurrent topics in Maja Bujas‐Bobanovic's work include Lipoproteins and Cardiovascular Health (19 papers), Diabetes Treatment and Management (11 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Maja Bujas‐Bobanovic is often cited by papers focused on Lipoproteins and Cardiovascular Health (19 papers), Diabetes Treatment and Management (11 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Maja Bujas‐Bobanovic collaborates with scholars based in United States, France and Canada. Maja Bujas‐Bobanovic's co-authors include Serdar Dursun, H.A. Robertson, Lawrence A. Leiter, Kausik K. Ray, Bertrand Cariou, Helen M. Colhoun, Michael J. Louie, Alexia Letierce, Stefano Del Prato and Francisco J. Tinahones and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Maja Bujas‐Bobanovic

29 papers receiving 699 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maja Bujas‐Bobanovic United States	17	454	183	163	104	80	29	731
Eleanor Clune Australia	7	102 0.2×	35 0.2×	194 1.2×	361 3.5×	181 2.3×	9	660
M. Vergeer Netherlands	10	179 0.4×	10 0.1×	110 0.7×	82 0.8×	92 1.1×	12	531
Kay Dunn United States	11	127 0.3×	12 0.1×	106 0.7×	159 1.5×	35 0.4×	14	638
Steven E. Arnold United States	7	123 0.3×	48 0.3×	37 0.2×	44 0.4×	27 0.3×	8	375
Elisabeth A. Rosenthal United States	15	80 0.2×	17 0.1×	71 0.4×	61 0.6×	20 0.3×	46	677
Anthony Barron United Kingdom	12	139 0.3×	63 0.3×	65 0.4×	424 4.1×	7 0.1×	21	733
Ankit Shah United States	12	130 0.3×	13 0.1×	248 1.5×	56 0.5×	14 0.2×	43	669
Madhuja Mallick United States	8	100 0.2×	19 0.1×	99 0.6×	33 0.3×	44 0.6×	20	508
Lynn A. Hillger United States	11	157 0.3×	31 0.2×	91 0.6×	70 0.7×	7 0.1×	12	535

Countries citing papers authored by Maja Bujas‐Bobanovic

Since Specialization

Citations

This map shows the geographic impact of Maja Bujas‐Bobanovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maja Bujas‐Bobanovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maja Bujas‐Bobanovic more than expected).

Fields of papers citing papers by Maja Bujas‐Bobanovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maja Bujas‐Bobanovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maja Bujas‐Bobanovic. The network helps show where Maja Bujas‐Bobanovic may publish in the future.

Co-authorship network of co-authors of Maja Bujas‐Bobanovic

This figure shows the co-authorship network connecting the top 25 collaborators of Maja Bujas‐Bobanovic. A scholar is included among the top collaborators of Maja Bujas‐Bobanovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maja Bujas‐Bobanovic. Maja Bujas‐Bobanovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schwartz, Gregory G., Michael Szarek, Deepak L. Bhatt, et al.. (2023). Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. European Heart Journal. 27 indexed citations

Ray, Kausik K., Stefano Del Prato, Dirk Müller‐Wieland, et al.. (2019). Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovascular Diabetology. 18(1). 149–149. 27 indexed citations

Ray, Kausik K., Lawrence A. Leiter, Dirk Müller‐Wieland, et al.. (2018). Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial. Diabetes Obesity and Metabolism. 20(6). 1479–1489. 71 indexed citations

Leiter, Lawrence A., Francisco J. Tinahones, Dean G. Karalis, et al.. (2018). Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabetic Medicine. 35(12). 1742–1751. 19 indexed citations

Ginsberg, Henry N., Michel Farnier, Jennifer G. Robinson, et al.. (2018). Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Therapy. 9(3). 1317–1334. 19 indexed citations

Taskinen, Marja‐Riitta, Stefano Del Prato, Maja Bujas‐Bobanovic, et al.. (2018). Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis. 276. 124–130. 24 indexed citations

Henry, Robert R., Dirk Müller‐Wieland, Pam R. Taub, et al.. (2018). Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. Diabetes Obesity and Metabolism. 20(7). 1632–1641. 9 indexed citations

Leiter, Lawrence A., Bertrand Cariou, Dirk Müller‐Wieland, et al.. (2017). Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial. Diabetes Obesity and Metabolism. 19(12). 1781–1792. 100 indexed citations

Cariou, Bertrand, Lawrence A. Leiter, Dirk Müller‐Wieland, et al.. (2017). Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial. Diabetes & Metabolism. 43(5). 453–459. 19 indexed citations

10.

Leiter, Lawrence A., Francisco J. Tinahones, Dean G. Karalis, et al.. (2017). ALIROCUMAB SAFETY IN INDIVIDUALS WITH AND WITHOUT DIABETES MELLITUS: POOLED DATA FROM 14 ODYSSEY TRIALS. Journal of the American College of Cardiology. 69(11). 1674–1674. 3 indexed citations

11.

Müller‐Wieland, Dirk, Lawrence A. Leiter, Bertrand Cariou, et al.. (2017). Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular Diabetology. 16(1). 70–70. 21 indexed citations

12.

Ray, Kausik K., Henry N. Ginsberg, Michael H. Davidson, et al.. (2016). Abstract 18484: Modest Potential Association Between Reductions in Lipoprotein(a) and Major Adverse Cardiovascular Events in the Phase 3 Trials of Alirocumab versus Control. Circulation. 3 indexed citations

13.

Dwyer, Jamie P., Helen M. Colhoun, Francisco J. Tinahones, et al.. (2016). Abstract 16850: Effect of Alirocumab in Patients With Diabetic Dyslipidemia and Chronic Kidney Disease. 134. 1 indexed citations

14.

Roth, Eli M., Maja Bujas‐Bobanovic, Michael J. Louie, & Bertrand Cariou. (2015). Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. Clinical Therapeutics. 37(9). 1945–1954.e6. 25 indexed citations

15.

Telner, Deanna, Maja Bujas‐Bobanovic, David W. Chan, et al.. (2010). Game-based versus traditional case-based learning. Canadian Family Physician. 56(9). 4 indexed citations

16.

Kutcher, Stan, et al.. (2003). Short-term educational intervention improves family physicians' knowledge of depression. Journal of Continuing Education in the Health Professions. 23(4). 239–243. 6 indexed citations

17.

Kutcher, Stan, et al.. (2002). Evaluating the Impact of an Educational Program on Practice Patterns of Canadian Family Physicians Interested in Depression Treatment. The Primary Care Companion For CNS Disorders. 4(6). 224–231. 15 indexed citations

18.

Bird, Diane, Maja Bujas‐Bobanovic, H.A. Robertson, & Serdar Dursun. (2001). Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology. 155(3). 299–309. 42 indexed citations

19.

Bujas‐Bobanovic, Maja, et al.. (2000). Blockade of phencyclidine‐induced effects by a nitric oxide donor. British Journal of Pharmacology. 130(5). 1005–1012. 70 indexed citations

20.

Bujas‐Bobanovic, Maja, H.A. Robertson, & Serdar Dursun. (2000). Effects of nitric oxide synthase inhibitor NG-nitro-l-arginine methyl ester on phencyclidine-induced effects in rats. European Journal of Pharmacology. 409(1). 57–65. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact